Moderna posts surprise profit

Moderna sales get lift from early nod for newest COVID shot
Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s COVID boosters.
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna Delivers Surprise Q3 Profit as Cost-Cutting and Strong COVID Vaccine Sales Drive Growth
Moderna surprised Wall Street with a third-quarter profit on Thursday, driven by robust COVID-19 vaccine sales and significant cost-cutting measures. The Cambridge, Massachusetts-based biotech company posted net income of $13 million,
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine Sales
Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales. Moderna’s earnings per share and revenue surpassed Wall Street expectations, with earnings reaching a surprising profit and revenue exceeding projected figures.
Seeking Alpha on MSN2d
Moderna swings to profits as new COVID shot powers Q3 beat
Shares of Moderna (NASDAQ:MRNA) traded ~7% higher in the premarket ... The mRNA-based vaccine maker attributed the sales ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
BioPharma Dive2d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
pharmaphorum3d
Moderna says COVID/flu shot clears phase 3 hurdle
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK ...
NBC News on MSN6d
Do the Covid vaccines provide long-lasting protection?
In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...
AOL6d
Some people will need an extra Covid vaccine in the spring
In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid vaccine to bolster their ... the mRNA vaccines from Pfizer and Moderna — ...